A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis

NCT07489885 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2026-03-27

No results posted yet for this study

Summary

A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis

Conditions

Interventions

DRUG

D-2570 Tablet

Active Treatment

DRUG

Placebo Tablets

Identical Tablet

Sponsors & Collaborators

  • InventisBio Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-31
Primary Completion
2027-08-31
Completion
2027-12-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07489885 on ClinicalTrials.gov